9:00am - 5:00pm

Office Hours Mon. - Fri.

800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Archive

A Study of RO5509554 as Monotherapy and in Combination With Paclitaxel in Participants With Advanced Solid Tumors

Condition Advanced Solid Tumors Estimated Enrollment: 217 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: BP27772|2011-003394-28 Study First Received: December 2, 2011 Last Updated: November 1, 2016 Estimated Primary Completion Date: April 2018 Primary Outcome Measures: Percentage of Participants With Adverse Events|Part 1: Maximum Tolerated Dose (MTD)/Optimal Biological Dose (OBD) of RO5509554 as a Single Agent and in Combination With Paclitaxel|Part 2: Change in Colony Stimulating Factor-1 (CSF-1) Serum Level For Every 2 Weeks (Q2W) Schedule|Part 2: Change in CSF-1 Serum Level For Every 3 Weeks (Q3W) Schedule|Part 2: Change in...

Continue reading

French National Registry of Rare Peritoneal Surface Malignancies

Condition Rare Peritoneal Surface Malignancies|Pseudomyxoma Peritonei|Peritoneal Mesothelioma|Desmoplastic Small Round Cell Tumor|Psammocarcinoma|Primary Peritoneal Serous Carcinoma|Diffuse Peritoneal Leiomyomatosis|Appendiceal Mucinous Neoplasms Estimated Enrollment: 2171 Age Group: Child, Adult, Senior Gender: All Study Type: Observational Study Design Allocation: Observational Model: Cohort Study ID Numbers: 69HCL16_0406 Study First Received: June 30, 2016 Last Updated: July 12, 2016 Estimated Primary Completion Date: December 2018 Primary Outcome Measures: Incidence of rare peritoneal surface malignancies|Impact of specific treatment strategies Sponsors and Collaborators: Hospices Civils de Lyon Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02834169...

Continue reading

Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin

Condition Malignant Pleural Mesothelioma|Nonsquamous Nonsmall Cell Neoplasm of Lung Estimated Enrollment: 31 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: ONC-2011-001 Study First Received: May 24, 2013 Last Updated: February 9, 2017 Estimated Primary Completion Date: May 2016 Primary Outcome Measures: To determine the dose limiting toxicities (DLTs) of Tivantinib|To determine the pharmacokinetics profile of Tivantinib in combination with Carboplatin and Pemetrexed|To assess the preliminary anti-tumor activity of Tivantinib with PFS|To assess the preliminary anti-tumor activity of Tivantinib with RECIST|To evaluate dynamic changes in blood levels|To evaluate the expression of biomarkers|To...

Continue reading

Gene Therapy for Pleural Malignancies

Condition Pleural Mesothelioma|Metastatic Pleural Effusions Estimated Enrollment: 18 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: 803776|P01CA066726 Study First Received: March 3, 2006 Last Updated: February 21, 2017 Estimated Primary Completion Date: April 2023 Primary Outcome Measures: To determine toxicity of two doses of intrapleural BG00001 (Ad.hIFN-β over 8 days, and|To assess systemic and intrapleural cytokine responses as well as cellular and humoral immune responses after repeated BG00001 instillation,|and to assess, in a preliminary way, efficacy via tumor regression, time to progression and survival. Sponsors and Collaborators: University of Pennsylvania|National Cancer Institute...

Continue reading

CART-meso in Mesothelin Expressing Cancers

Condition Metastatic Pancreatic (Ductal) Adenocarcinoma|Epithelial Ovarian Cancer|Malignant Epithelial Pleural Mesothelioma Estimated Enrollment: 19 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: UPCC31213 Study First Received: June 6, 2014 Last Updated: March 16, 2017 Estimated Primary Completion Date: November 2015 Primary Outcome Measures: Number of Adverse Events Sponsors and Collaborators: University of Pennsylvania Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02159716...

Continue reading

Autologous Redirected RNA Meso-CIR T Cells

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 18 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: UPCC 17510 Study First Received: May 17, 2011 Last Updated: October 18, 2016 Estimated Primary Completion Date: July 2015 Primary Outcome Measures: Adverse Events|Clinical response Rate Sponsors and Collaborators: University of Pennsylvania Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01355965...

Continue reading

Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT)

Condition Lung Cancer|Mesothelioma Estimated Enrollment: 22 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: 2010-0057|NCI-2011-02080 Study First Received: May 27, 2010 Last Updated: November 9, 2016 Estimated Primary Completion Date: May 2018 Primary Outcome Measures: Maximum Tolerated Dose (MTD) of IMRT after radical pleurectomy/decortication (PD) Sponsors and Collaborators: M.D. Anderson Cancer Center Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01134146...

Continue reading

Intra-pleural Administration of GL-ONC1, a Genetically Modified Vaccinia Virus, in Patients With Malignant Pleural Effusion: Primary, Metastases and Mesothelioma

Condition Lung Cancer Estimated Enrollment: 18 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: No masking|Primary Purpose: Treatment Study ID Numbers: 12-169 Study First Received: January 9, 2013 Last Updated: January 27, 2017 Estimated Primary Completion Date: January 2018 Primary Outcome Measures: Maximum Tolerated Dose (MTD)|safety|detection of virus in body fluids|evaluation of viral appearance in tumor|Therapeutic efficacy Sponsors and Collaborators: Memorial Sloan Kettering Cancer Center|Genelux Corporation Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01766739...

Continue reading

Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 60 Age Group: 18 Years and older   (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Participant, Investigator)|Primary Purpose: Treatment Study ID Numbers: 2011-0289|HRPO Log Number A-15872|NCI-2010-02375|W81XWH-10-1-0699 Study First Received: June 27, 2013 Last Updated: October 6, 2016 Estimated Primary Completion Date: December 2018 Primary Outcome Measures: 1-Year Progression Free Survival Sponsors and Collaborators: M.D. Anderson Cancer Center|U.S. Army Medical Research and Materiel Command|Memorial Sloan Kettering Cancer Center|Sellas Life Sciences Group Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01890980...

Continue reading

Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients

Condition Malignant Pleural Mesothelioma Estimated Enrollment: 150 Age Group: Child, Adult, Senior Gender: All Study Type: Observational Study Design Allocation: Observational Model: Case-Only|Time Perspective: Retrospective Study ID Numbers: ONC/OSS-02/2012 Study First Received: May 27, 2013 Last Updated: February 9, 2017 Estimated Primary Completion Date: December 2016 Primary Outcome Measures: Expression of TUBB3 and BRCA1 in MPM tumor tissue by immunohistochemistry and RT-PCR.|Association of expression of TUBB3 and BRCA1 with clinical outcome (response, survival) . Sponsors and Collaborators: Armando Santoro, MD|Istituto Clinico Humanitas Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT01865045...

Continue reading